Metabolic and atherosclerosis Research center

Cincinnati, Ohio 45229

0 studies enrolling now · 16 studies all time

What they study most

ASCVD, Atherosclerotic Cardiovascular Disease, Cardiovascular Disease, Diabetes, Dyslipidemia, Dyslipidemias, Elevated Lp(a), Familial Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia, High Cholesterol, Hypercholesterolemia, Hyperlipidemia

Studies at this site

• Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies — Completed
• Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a) — Completed
• Randomized Study of Obicetrapib as an Adjunct to Statin Therapy — Completed
• Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL — Paused
• Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C) — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia — Completed
• Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia — Status unconfirmed
• Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis — Completed
• Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia — Stopped early
• The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects — Completed
• Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy — Stopped early
• Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy — Stopped early
• Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy — Stopped early